KNSA has been the topic of a number of other reports. Zacks Investment Research lowered Kiniksa Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, January 1st. Goldman Sachs Group raised Kiniksa Pharmaceuticals from a neutral rating to a buy rating and upped their price objective for the stock from $16.00 to $18.00 in a research report on Friday, December 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $21.75.
Shares of KNSA stock traded up $0.52 during trading hours on Wednesday, hitting $15.26. 9,407 shares of the company were exchanged, compared to its average volume of 307,087. Kiniksa Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $25.79. The business has a 50 day moving average of $12.18 and a two-hundred day moving average of $10.24. The company has a market capitalization of $806.74 million, a PE ratio of -4.30 and a beta of -0.95.
Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals by 195.8% in the second quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Kiniksa Pharmaceuticals by 14.4% during the 2nd quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock worth $14,990,000 after buying an additional 139,072 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Kiniksa Pharmaceuticals by 300.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 140,000 shares of the company’s stock valued at $1,191,000 after acquiring an additional 105,000 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Kiniksa Pharmaceuticals by 68.3% in the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after acquiring an additional 25,970 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Kiniksa Pharmaceuticals by 17.1% in the second quarter. Northern Trust Corp now owns 154,899 shares of the company’s stock valued at $2,097,000 after acquiring an additional 22,645 shares during the last quarter. 29.85% of the stock is owned by institutional investors.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.